We have investigated the effect of misonidazole (MISO) on the pharmacokinetics of 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) in mice. CCNU and its monohydroxylated metabolites were measured using a high performance liquid chromatography (HPLC) method. In the absence of MISO the plasma disappearance of CCNU was biphasic with a tf, of 2.3 min and a tq of 53 min. The monohydroxylated metabolites of CCNU also followed biphasic clearance kinetics. A large single dose of MISO (0.5mgg-'), given i.p. 30min prior to CCNU, prolonged the tla by a factor of 2.6 but had no effect on tip In addition, the apparent volume of distribution was decreased by a factor of 1.6. Consequently, the plasma area under the curve (AUCO .) was increased by a factor of 1.7 for CCNU and by a factor of 2.0 for total nitrosourea (CCNU+monohydroxylated metabolites). The effects of MISO on CCNU kinetics were dependent on MISO dose and plasma concentration and on the interval between MISO and CCNU administration. The concentration of CCNU was measured in 4 tumours: the KHT, RIF-1 and EMT6 mouse tumours, and the HT29 xenograft. For all 4 tumours, 0.5mgg-' MISO raised the tumour concentrations of CCNU and total nitrosourea by a considerable amount (2-2.5 times). More detailed studies in the KHT tumour demonstrated that there was a significant lag period before peak tumour CCNU concentrations were reached, and that MISO increased the peak concentrations by a factor of about 2.4. In contrast, there was no such lag period for the plasma and MISO did not increase the plasma peak CCNU concentrations. These data strongly suggest that modification of the pharmacokinetics may be a major contributory factor in the enhancement of CCNU cytotoxicity by large single doses of MISO in vivo.
Many studies have shown that electron affinic radiation sensitizers such as misonidazole (MISO) can enhance the cytotoxic efficacy of a number of anti-cancer agents against tumours in mice (for review see McNally, 1982; Siemann, 1982a) . In most cases, the enhancements were greater in tumours than in normal tissues resulting in a therapeutic gain. A number of clinical trials are now in progress.
The mechanism of action by which MISO exerts its chemosensitising effect is unknown, although a number of possible mechanisms have been discussed (Brown, 1982; Millar, 1982; Siemann, 1982a) . In view of the selective enhancement of tumour toxicity, most investigators have favoured hypoxiamediated mechanisms acting at the cellular level, e.g. inhibition of DNA repair processes or depletion of intracellular thiols. However, studies in our laboratory have shown that MISO also inhibits the hepatic drug-metabolising enzymes suggesting that the mechanism may involve changes in cytotoxic drug pharmacokinetics . Some evidence in favour of altered pharmacokinetics has been obtained for melphalan (Clutterbuck et al., 1982), mice. KHT, RIF-1 and EMT6 tumours were grown in the gastrocnemius muscles of the hind leg as described by Twentyman et al. (1979) . The HT29 human colonic adenocarcinoma xenograft was grown bilaterally from s.c. injections in the flank as described for the HT29R line by Warenius & Bleehen (1982) . Unless otherwise stated data reported are for C3H/He mice.
Drug administration CCNU was first dissolved in a 1:1 mixture of ethanol/Cremophor-EL (Sigma) and then diluted 1:4 with saline. In this form CCNU remains stable for at least 8 h at room temperature as determined by high-performance liquid chromatography (HPLC) assay. This solution was injected in 0.01 ml gbody weight.
MISO was dissolved in Hanks' balanced salt solution and injected i.p. in 0.04 ml g-' body
weight.
In most experiments mice received 0.5 mg g-1 (2.5mmolkg-') MISO followed by an appropriate dose of CCNU 30 min later. In some experiments a range of MISO doses (0.1-1.Omgg-1) was used, while in others CCNU was given at varying intervals (0.5-6 h) after MISO. In all instances controls were given the appropriate vehicles. Sample preparation Blood was drawn by heart puncture into heparinized syringes (0.5-0.8 ml per mouse). This was immediately cooled on ice and pooled with blood from mice of the same group. (Workman & Brown, 1981) . Pharmacokinetic parameters were calculated as described previously (Workman & Brown, 1981; White & Workman, 1980 Figure 1 shows the typical pharmacokinetics of MISO given i.p. at a dose of 0.5mgg-'. CCNU, at a dose of 20mg ml-1 i.p. administered 0.5 h following MISO, had no significant effect on MISO pharmacokinetics. The plasma decay curve gives an apparent ti value (Workman, 1980a) HPLC of CCNU and its metabolites CCNU is metabolized rapidly by the liver microsomal mixed function oxidase system to ringmonohydroxylated products (Hilton & Walker 1975 ). Five of the 6 possible isomeric metabolites were detected in the plasma of our mice. isomers which reflects their partition coefficients: thus the order is trans-4-hydroxy, cis-4-hydroxy, cis-3-hydroxy, trans-3-hydroxy, trans-2-hydroxy and cis-2-hydroxy CCNU. We have therefore assigned peaks 2, 3 and 4 as the cis-4, cis-3 and trans-3-hydroxy CCNU respectively.
Pharmacokinetics of MISO in mice
Pharmacokinetics of CCNU and the effects of MISO pretreatment Figure 3 shows all the data obtained on the plasma pharmacokinetics of CCNU in mice. Absorption of an i.p. administered dose (20mg kg-1) was extremely rapid, with peak plasma concentration being reached within 2 min after injection. The plasma clearance of CCNU follows biexponential kinetics, with a rapid initial (a) phase followed by a slower terminal (,B) phase. The c and ,B components are normally regarded as the distribution and elimination phases respectively. In this case a considerable amount of metabolism occurs during the ac-phase (see later), and the terminal elimination may be limited by the rate of redistribution of CCNU from tissue depots back into the plasma. Table II. Following MISO administration the clearance of the main trans-4 hydroxy metabolites and of the total nitrosoureas appeared to become monophasic, whereas the clearance of the other metabolites remained biphasic (Figure 4) . Concentrations of all the metabolites were increased by MISO. AUCOG- (Table II) . However the terminal ti values were not significantly altered by MISO (P>0.1) indicating that the main effects occurred during the production and initial clearance of the metabolites. It should be noted that the peak concentration of the total nitrosoureas was not affected by MISO (Figure 4 ) whereas the AUCO0_ was increased by a factor of 2.
The lack of effects on the f-phase clearance is consistent with the hypothesis that the rate-limiting process of the fl-phase plasma clearance of CCNU and metabolites is not hepatic metabolism but the redistribution from tissue depots as adipose tissue back into the plasma. A possible alternative explanation was that the concentration of MISO in plasma may have dropped below the inhibitory level during the fl-phase. This was ruled out because in an experiment where 0.5 mg g1 MISO was given during the early #-phase of CCNU clearance (1 h after CCNU), there was again no significant change in the ty (P>0.1, data not shown). However the apparent volume of distribution again appeared to be reduced.
CCNU dose modification by MISO Figure 5 shows the concentrations of total nitrosoureas in the plasma of mice given CCNU Figure 6B . MISO was found to be most effective when given 0.5-1 h prior to CCNU. Its effectiveness was reduced with increasing interval up to 4 h, and no effects were observed at 6 h.
Effects of MISO on the CCNU concentrations in tumours
Several experiments were carried out to determine . oW the effect of MISO on the concentrations of CCNU < \ in 3 transplantable mouse tumours (KHT, RIF- 1 1 0 and EMT6) and the HT29 colon carcinoma xenograft. Figure 7 shows all the data obtained. The ratio of tumour/plasma CCNU concentrations was tumour dependent: KHT and HT29 gave relatively high ratios, EMT6 an intermediate, and RIF-l a low ratio (Table III) . Tumour/plasma ratios were not altered by 0.5mgg-1 MISO (Table   III) Results shown are mean + 2 s.e. of 3-6 determinations.
inadequate blood supply. MISO increased the peak tumour concentration by a factor of -2.4.
Binding of CCNU to plasma protein Table IV shows the extent to which CCNU and its major metabolite, trans-4 monohydroxylated CCNU, bind to mouse plasma proteins. At concentrations up to 0.5mg ml-1 (2.5 mM) MISO did not appear to affect the binding of the nitrosoureas; this was found to be the case for both in vivo and in vitro binding. (39-47) min and 40 (36-46) min respectively.
Discussion
The results of these studies clearly show that single high doses of MISO reduced the rate of plasma clearance of CCNU and its active metabolites. The tumour concentrations of CCNU generally reflect the plasma concentrations, and therefore MISO has the effect of increasing the tumour exposure to the cytotoxic nitrosoureas.* The pharmacokinetics of CCNU, not described in such detail previously, appear to involve a rapid initial clearance due to metabolism to the *It may be significant that the magnitude of the tumour/plasma ratios of the 3 murine tumours KHT, EMT6 and RIF-1 also reflect their in vivo sensitivity to CCNU. hydroxylated metabolites; this is followed by a slower terminal clearance probably limited by slow release of the highly lipophilic CCNU from hydrophobic depots, such as adipose tissue. The initial kinetics of the increased concentrations of CCNU and its hydroxylated metabolites are consistent with a model in which MISO inhibits the hydroxylation of CCNU and may also inhibit the subsequent metabolism of the hydroxylated derivatives to unknown species. The increased levels of CCNU at later times were due to a reduction in the volume of distribution, and a similar effect may also occur with the metabolites. The mechanism by which MISO decreases the apparent volume of distribution of CCNU is not known, but may involve a reduced penetration of the drug into, or a reduced retention by, certain body tissue depots. Both MISO (Shoemaker et al., 1982) and the nitrosoureas (Walker & Hilton 1976 ) are metabolized by the liver mixed function oxidase enzymes and it is likely that MISO may act as a competitive inhibitor of nitrosourea metabolism. Experiments are in progress to determine the nature of the inhibition in liver microsomal preparations. The inhibition is not due to the hypothermia seen with higher doses ofMISO (Gomer & Johnson, 1979) Siemann, 1981 Siemann, , 1982b . The mechanism of action of MISO chemosensitisation is not fully understood, but in view of the increase in the plasma and tumour levels of cytotoxic nitrosoureas by 0.5mgg-1 MISO it is likely that pharmacokinetic modification is an important contributory mechanism. In support of this we found that the MISO dose needed to produce significant reduction of CCNU clearance had to be > 0.3mg g-, and this correlates well with the doses required for effective chemosensitisation. The effect of the timing of the two drugs is also similar for pharmacokinetic changes and chemosensitization. Several other lines of evidence support the pharmacokinetic mechanism. SKF-525-A, the classical inhibitor of xenobiotic detoxification enzymes, has been shown to produce excellent enhancement of CCNU cytotoxicity Siemann, 1983) . We have also demonstrated a therapeutic gain for this combination (Workman & Twentyman, in preparation) , but Siemann (1983) found that the normal tissue toxicity was also increased. Other studies in our laboratory have clearly demonstrated inhibition of drug metabolising enzymes by MISO ), and we have also shown that MISO slows the clearance of chlorambucil and melphalan (Workman et al., 1983, Lee & Workman unpublished) . Other laboratories have found that MISO reduces the clearance of melphalan (Clutterbuck et al., 1982; McNally et al., personal communication) and the active metabolites of cyclophosphamide and BCNU (Tannock, 1980; McNally et al., personal communication) .
Our results on the pharmacokinetics of CCNU provide a possible explanation for the therapeutic gain with the combination of MISO and CCNU. MISO increased the peak tumour concentration of CCNU and total nitrosoureas without increasing the peak plasma concentration. This was due to the fact that peak tumour levels lag behind the peak plasma levels, probably because of inadequate tumour blood supply. If the peak nitrosourea concentration is more important for cytotoxicity than overall exposure, and if the better perfused dose-limiting normal tissues (gut and bone marrow) follow the plasma concentration more closely than the tumour, then the differential effect of MISO will result in a therapeutic gain. We are now developing methods to assay nitrosoureas in bone marrow and gut.
Differences in the pharmacokinetics of various nitrosoureas may provide an alternative explanation for the interesting chemosensitization data of Mulcahy (1982) who reported a good correlation between the dose-modifying factor produced by pretreatment with MISO and the relative carbamoylating activities of individual nitrosoureas. However, the order of relative carbamoylating activities of the nitrosoureas studied also correlates with increasing relative partition coefficient which generally determines whether or not a drug is metabolized by hepatic enzymes.
The important question is whether the MISO effect can be obtained with clinically relevant doses. The doses of MISO used in experimental studies have generally been in the range of 0.3-lmgg-1 (1.5-5 mmol kg-) giving peak plasma concentrations of 300-1000 jg ml-1 (1.5-5 mM). In the clinic the largest single dose normally given to patients (3gm-2) produces a peak plasma concentration of only 100 pg ml-1 (0.5 mM) (Workman, 1980b) .
However, the plasma half-life of MISO in man is 10-20 times longer than in the mouse (Workman, 1980b) . We have therefore tried to mimic human pharmacokinetics in mice by giving multiple small doses of MISO . Preliminary results have indicated no appreciable change in CCNU pharmacokinetics when plasma MISO concentrations were maintained at about 90pgml-1 for over 4 h prior to CCNU treatment (Lee & Workman unpublished) and this probably explains our observed lack of chemosensitization with this regime . In contrast, did observe chemosensitization with this regime, and the disparity may be due to the proximity of the MISO plasma concentration to the threshold for changes in pharmacokinetics and chemosensitization. In experiments in the dog, which is a better model for human MISO metabolism (White et al., 1979) , a relatively low dose of MISO (150mgkg-1 i.v.) given immediately before CCNU (5mg kg 1 i.v.) has produced significant changes in the clearance of CCNU and its metabolites (Lee et al., unpublished) .
We have recently found that the HPLC method can be used to determine the pharmacokinetics of CCNU and its metabolites in man, and this is now being used to investigate the pharmacokinetic interactions between nitroimidazoles and CCNU in patients.
It should be emphasized that while the alterations in CCNU pharmacokinetics by MISO described here appear to explain the therapeutic gain for this combination, we have at present no comparable detailed data to support a similar mechanism for the therapeutic gain seen with other cytotoxic agents. We feel that poor penetration of cytotoxic drugs into tumours at early times may be involved, and experiments are in progress to test this.
